Johnson & Johnson ADVANCED — Sales to customers (Note 9) increased by 0.1% to $2.33B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 5.0%, from $2.22B to $2.33B. Over 2 years (FY 2021 to FY 2024), ADVANCED — Sales to customers (Note 9) shows an upward trend with a 8.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates growing market adoption and successful commercialization of advanced product offerings, while a decrease may signal competitive pressure or product lifecycle maturity.
This metric represents the total revenue generated from the Advanced product segment, reflecting the market demand for t...
Comparable to segment-specific revenue reporting in medical device or pharmaceutical peers, often benchmarked against total segment revenue growth rates.
jnj_segment_advanced_sales_to_customers_note_9| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.24B | $2.34B | $2.29B | $2.35B | $2.29B | $2.31B | $2.32B | $2.24B | $2.33B | $2.17B | $2.28B | $2.22B | $2.30B | $2.15B | $2.33B | $2.33B |
| QoQ Change | — | +4.4% | -2.0% | +2.5% | -2.3% | +0.9% | +0.2% | -3.5% | +4.2% | -6.6% | +5.0% | -2.8% | +3.8% | -6.8% | +8.5% | +0.1% |
| YoY Change | — | — | — | — | +2.5% | -1.0% | +1.2% | -2.5% | +0.7% | — | +2.1% | -4.7% | — | -1.3% | +2.0% | +5.0% |
We use cookies for analytics. See our Privacy and Cookie Policy.